Literature DB >> 28301048

Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations.

A Blauvelt1, C E M Griffiths2, M Lebwohl3, U Mrowietz4, L Puig5, S Ball6, L Zhang6, E Edson-Heredia6, M Warner6, B Zhu6, C-Y Lin6, E Nikaï7, D Dey6, L Mallbris6, K Reich8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28301048     DOI： 10.1111/bjd.15463

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  5 in total

1.  Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis.

Authors:  Adelaide A Hebert; Margaret A Bobonich; Claudia Rodriguez Capriles; Gaia Gallo; Lingnan Li; Najwa Somani; Terri Ridenour; Yan Wang; Emily Edson-Heredia; Emily M Becker
Journal:  Pediatr Dermatol       Date:  2021-12-20       Impact factor: 1.997

2.  A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).

Authors:  J Seneschal; J-P Lacour; A Bewley; M Faurby; C Paul; G Pellacani; C De Simone; L Horne; A Sohrt; M Augustin; E Hammond; K Reich
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-06-08       Impact factor: 6.166

3.  Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.

Authors:  M Gooderham; A Pinter; L K Ferris; R B Warren; T Zhan; J Zeng; A M Soliman; C Kaufmann; B Kaplan; H Photowala; B Strober
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-03-17       Impact factor: 9.228

4.  Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.

Authors:  Craig Leonardi; Kristian Reich; Peter Foley; Hideshi Torii; Sascha Gerdes; Lyn Guenther; Melinda Gooderham; Laura K Ferris; Christopher E M Griffiths; Hany ElMaraghy; Heidi Crane; Himanshu Patel; Russel Burge; Gaia Gallo; David Shrom; Ann Leung; Chen-Yen Lin; Kim Papp
Journal:  Dermatol Ther (Heidelb)       Date:  2020-03-21

5.  Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).

Authors:  Jean-Philippe Lacour; Anthony Bewley; Edward Hammond; Jes B Hansen; Laura Horne; Carle Paul; Kristian Reich; Julien Seneschal; Clara De Simone; Anne Sohrt; Matthias Augustin; Giovanni Pellacani
Journal:  Dermatol Ther (Heidelb)       Date:  2020-08-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.